Intratumoral IL-12 is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of Intratumoral IL-12 with DNA-based IL-12 demonstrated the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. This technology employs electroporation, which involves the use of electrical pulses to increase the permeability of the cell membrane, permitting the DNA to enter the cells.
HOW IT WORKS
Genetically engineered DNA, designed to code for immune-stimulatory proteins, are administered or injected directly into a tumor (or tumors).
The needle applicator supplies a sequence of short-duration electrical pulses to the tumor. This increases permeability of the cell membrane and facilitates uptake of the DNA-based agent(s).
The cell membrane reseals and the electroporated cells manufacture the protein according to the specifications engineered into the DNA-based agent. Expression of immunomodulatory cytokines, antibodies, and other proteins can be expressed in-situ, leading to local and systemic effects.
Safety Profile Favorable safety profile supports ongoing clinical development of Intratumoral IL-12 with DNA-based IL-12. In clinical studies, TAVO has shown a favorable safety profile and has been generally well-tolerated across multiple treatment cycles with no treatment-related serious adverse events reported.
Anti-Tumor Activity with Abscopal Effect Data from our Phase II melanoma program provide preliminary evidence of anti-tumor activity with abscopal effect. These results paved the way for expansion of our immuno-oncology pipeline, including the design of a new study testing TAVO in triple negative breast cancer.
Cold to Hot Data indicates that local delivery and expression of TAVO promotes tumor immunogenicity and increases TILs. As a pro-inflammatory cytokine, IL-12 can promote the recruitment of T-cells to the tumor. By driving T-cells or TILs into the tumor microenvironment, TAVO may enhance response to anti-PD-1 and convert anti-PD-1 non-responders to responders.